Genmab — Marts 2013

[Budweis]

Experimental Roche drug (inclacumab
) shows promise in reducing heart damage

[gentogen]

http://www.theheart.org/article/1516411.do

[gentogen]

New drug inclacumab reduces heart damage

A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal. Presented today in San Francisco at the prestigious American cardiology conference, these findings show great promise.

Medical Xpress (medicalxpress.com)

[deleted-user]

ja mon ikke de tager den i fase 3. Det vil jeg tro de gør 75-25

[Solsen]

Domain Registered at Safenames

(www.biomedexperts.com)

[Solsen]

New drugs might give heart patients an edge

(HealthDay)—In the search for better medicines to safely help heart patients, clinical trials testing three new drugs appear to offer some promise.

Medical Xpress (medicalxpress.com)

[Solsen]

Sidst i linket siges at større forsøg er på v ej

[deleted-user]

Hvem er ham Tardif?

[MadsSkjern]

Hotshot kardiolog i Canada http://www.genomequebec.com/1149-investigator/jean-claude-tardif.html

[deleted-user]

jeg kan ikke rigtigt åbne det link

[MadsSkjern]

Jean-Claude Tardif is presently the director of the research center at the Montreal Heart Institute, professor of medicine at the University of Montreal, and founder of the new University of Montreal Pharmacogenomics Centre. Dr. Tardif is a world leader in cardiovascular research and has made groundbreaking contributions to the fields of atherosclerosis and biomarkers to assess anti-atherosclerotic therapies. He has published 180 scientific articles in prestigious journals, written 25 book chapt

[deleted-user]

ok.

[gentogen]

Duo Body http://www.pnas.org/content/early/2013/03/08/1220145110.full.pdf+html

[gentogen]

This superior activity does, however, suggest that some antibody
pairs may benefit more from a bsAb approach than from a combination
strategy.

[gentogen]

using cFAE to create bsIgG1 ensures a proper in
vivo half-life, intact Fc effector functions, and good manufacturability
while retaining a regular IgG structure.

[gentogen]

Proof-of-concept studies with HER2×CD3 (T-cell recruitment)
and HER2×HER2 (dual epitope targeting) bsAbs demonstrate
superior in vivo activity compared with parental antibody pairs.

[deleted-user]

Just a moment...

(www.pnas.org)

[deleted-user]

det her link er måske bedre

[120281]

går gang i Gen igen idag. 5% oppe.

[gentogen]

Clinical trials tæller 93 ofatumumab idag efter langtid at have haft 92. Jeg kan bare ikke finde det nye ...